At the time of writing, Amylyx Pharmaceuticals Inc [AMLX] stock is trading at $6.33, down -2.62%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AMLX shares have gain 25.35% over the last week, with a monthly amount glided 32.15%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] stock has seen the most recent analyst activity on June 24, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $17. Previously, Citigroup started tracking the stock with Buy rating on June 17, 2025, and set its price target to $12. On May 30, 2025, TD Cowen initiated with a Buy rating. Mizuho upgraded its rating to a Outperform but stick to its price target of $7 on April 07, 2025. Robert W. Baird upgraded its rating to a Outperform and raised its price target to $11 on November 18, 2024. BofA Securities upgraded its rating to Buy for this stock on October 23, 2024, and upped its price target to $10. In a note dated March 18, 2024, Mizuho downgraded an Neutral rating on this stock and revised its target price from $32 to $4.
For the past year, the stock price of Amylyx Pharmaceuticals Inc fluctuated between $1.62 and $7.27. Currently, Wall Street analysts expect the stock to reach $13.5 within the next 12 months. Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] shares were valued at $6.33 at the most recent close of the market. An investor can expect a potential return of 113.27% based on the average AMLX price forecast.
Analyzing the AMLX fundamentals
According to Amylyx Pharmaceuticals Inc [NASDAQ:AMLX], the company’s sales were -1.27M for trailing twelve months, which represents an -100.00% plunge. Gross Profit Margin for this corporation currently stands at 7.76% with Operating Profit Margin at 163.17%, Pretax Profit Margin comes in at 172.56%, and Net Profit Margin reading is 172.06%. To continue investigating profitability, this company’s Return on Assets is posted at -1.0, Equity is -1.06 and Total Capital is -1.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.08 points at the first support level, and at 5.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.59, and for the 2nd resistance point, it is at 6.84.
Ratios To Look Out For
It is important to note that Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] has a current ratio of 12.05. Further, the Quick Ratio stands at 12.05, while the Cash Ratio is 3.33.
Transactions by insiders
Recent insider trading involved FRATES JAMES M, Chief Financial Officer, that happened on Mar 31 ’25 when 10896.0 shares were sold. Chief Medical Officer, Bedrosian Camille L completed a deal on Mar 31 ’25 to sell 12425.0 shares. Meanwhile, Chief Legal Officer Mazzariello Gina sold 9192.0 shares on Mar 31 ’25.
